DUBLIN–(BUSINESS WIRE)–The “Combigan 2016 U.S. Promotional Report” report has been added to Research and Markets’ offering. The 5 Key Questions Addressed by this Report: How many physicians were reached by Combigan through personal promotion in 2016 …
Category: Business
U.S. Durezol Promotional Report 2016-2017 – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Durezol 2016 U.S. Promotional Report” report has been added to Research and Markets’ offering. The 5 Key Questions Addressed by this Report: How many physicians were reached by Durezol through personal promotion in 2016 an…
Hemovent Appoints Professor Alain Combes, MD, PhD, to Its Scientific Advisory Board
AACHEN, Germany–(BUSINESS WIRE)–Hemovent announced today it has established a Scientific Advisory Board with the appointment of Professor Alain Combes, MD, PhD, Professor of Intensive Care Medicine at Sorbonne University of Paris; and, head of the ICU department at the Institut de Cardiologie, Hôpital Pitié-Salpêtrière, Assistance Publique Hopitaux de Paris. Professor Combes’ research interests include mechanical circulatory assistance and extracorporeal membrane oxygenation. He is a member o
Presbia Announces Board and Management Changes and Financing Proposal to Operate Through to the End of 2018
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS, or the “Company”), an ophthalmic device company and leader in near-vision restoration, announces that it has re-ordered its operational priorities to focus its resources on FDA approval as well as ongoing clinical and commercial efforts in Germany and South Korea. These actions reduce the Company’s cash burn rate by eliminating pre-FDA approval marketing, manufacturing and engineering expenses related to the post-FDA approval U.S. commercial l
iVeena Delivery Systems Receives Notice of Allowance for Patent Protecting IVMED-10 & IVMED-20
SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems (iVeena), a biopharmaceutical company that develops innovative ophthalmology products, today announced that the United States Patent and Trademark Office (USPTO) communicated a Notice of Allowance for a patent assigned to the University of Utah and licensed to iVeena Delivery Systems Inc. The patent “Intraocular Drug Delivery Device and Associated Methods” covers methods to deliver dexamethasone to anterior and posterior eye segments to c
Aura Biosciences Announces Publication of Preclinical Data Supporting AU-011’s Potent and Selective Anti-cancer Activity in Ocular Melanoma Tumors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura announces publication of preclinical data supporting AU-011’s potent and selective anti-cancer activity in ocular melanoma tumors.
Announcing the Medical Device Development Collaborative (MD2C)
MINNEAPOLIS–(BUSINESS WIRE)–Medical device OEMs today are challenged by accessing the full range of product development capabilities necessary to advance new solutions from concept to market. To meet this challenge, a dedicated group of leading manuf…
ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Damien McDevitt, Ph.D., has joined ACADIA as Senior Vice President, Corporate Development, leading the company’s corporate development activities. He will report to Steve Davis, ACADIA’s President and Chief Executive Officer. “We a
Unum Dental available in all U.S. regions
CHATTANOOGA, Tenn.–(BUSINESS WIRE)–Unum (NYSE:UNM), a leading employee benefits provider, announced Unum Dental plans will be available in all regions of the country January 1, 2018.
Gecko Biomedical Named to FierceMedTech’s ‘Fierce 15’ List of Med Tech Companies for 2017
PARIS–(BUSINESS WIRE)–Gecko Biomedical (“Gecko”), a privately-owned life science company developing innovative polymers to support tissue reconstruction, announced today it has been named to the FierceMedTech 2017 Fierce 15 list of medical technology companies, designating it as one of the most promising private companies in the industry developing innovative medical technologies. Gecko Biomedical has a proprietary technology platform composed of fully synthetic light-activated polymers that
SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
CAMBRIDGE, Mass.–(BUSINESS WIRE)–SciFluor Life Sciences, Inc., a private, clinical stage company, today announced that the European Patent Office has issued a patent (EP 2953948) for SF0166, a novel potent and selective small molecule inhibitor of integrin αvβ3, in retinal diseases. This patent is supported by an additional 5 patents issued earlier by the U.S. Patent and Trademark Office (US 9,266,884, US 9,518,053, US 9,593,114, US 9,717,729, and US 9,802,933) which provide intellectual prop
Genentech Announces Phase III Data Showing Venclexta Plus Rituxan Reduced the Risk of Disease Progression or Death by 83 Percent Compared to a Standard of Care Regimen in Previously Treated Chronic Lymphocytic Leukemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the first results from the pivotal Phase III MURANO study evaluating Venclexta™ (venetoclax) plus Rituxan® (rituximab) compared to bendamustine plus Rituxan (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukemia (CLL). The results showed that a fixed duration of treatment with Venclexta plus Rituxan significantly reduced the risk o
Phase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death for the Initial Treatment of Certain People with Advanced Kidney Cancer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease express
Genentech’s HEMLIBRA (emicizumab-kxwh) Continued to Substantially Reduce Bleeds in People with Hemophilia A with Inhibitors
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from the ongoing HEMLIBRA® (emicizumab-kxwh) clinical development program were presented at the 59th American Society of Hematology (ASH) Annual Meeting. These data include longer-term results from the pivotal HAVEN 1 and HAVEN 2 studies in people with hemophilia A with inhibitors to factor VIII, showing once-weekly subcutaneous HEMLIBRA prophylaxis de
Georgia Ophthalmology Associates Joins EyeSouth Partners
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has expanded in the Atlanta metropolitan area by completing a strategic partnership with Georgia Ophthalmology Associates. EyeSouth is an eye care-focused physician services organization formed by Shore Capital Partners, a leading lower middle market healthcare private equity firm. Georgia Ophthalmology Associates was founded in 1978 by Dr. Stephen Leff and offers a full suite of medical and
Cohen Laser & Vision Center is Proud to Be the First to Introduce to South Florida the KAMRA® Corneal Inlay, a Solution to Eliminate Your Dependence on Reading Glasses
BOCA RATON, Fla.–(BUSINESS WIRE)–Cohen Laser and Vision Center of Boca Raton is introducing the KAMRA corneal inlay, an advanced solution for presbyopia, to South Florida.
NovaTears®+Omega-3 de Novaliq homologué en Europe pour le traitement amélioré de la sécheresse oculaire évaporative
HEIDELBERG, Allemagne–(BUSINESS WIRE)–Novaliq GmbH, une société pharmaceutique spécialisée avec une plateforme disruptive d’administration de médicaments transformant des médicaments peu solubles en produits ophtalmologiques efficaces, a annoncé aujourd’hui l’enregistrement européen de NovaTears®+Omega-3 pour le traitement amélioré des signes et des symptômes de la sécheresse oculaire (SO) évaporative. NovaTears®+Omega-3 constitue une percée technologique dans le traitement de la SO. Utilisan
NovaTears®+Omega-3 von Novaliq in Europa zur Verstärkung der Behandlung des evaporativen trockenen Auges zugelassen
HEIDELBERG, Deutschland–(BUSINESS WIRE)–Novaliq GmbH, ein spezialisiertes pharmazeutisches Unternehmen mit einer disruptiven Drug-Delivery-Plattform, die schwer lösliche Arzneimittel in wirksame Therapeutika für die Augenheilkunde verwandelt, meldete heute die europäische Zulassung von NovaTears®+Omega-3 zur Verstärkung der Behandlung der Anzeichen und Symptome des evaporativen trockenen Auges (Dry Eye Disease, DED). NovaTears®+Omega-3 ist ein technologischer Durchbruch in der DED-Behandlung.
Riassunto: NovaTears®+Omega-3 di Novaliq approvato in Europa per il trattamento dell’occhio secco evaporativo
HEIDELBERG, Germania–(BUSINESS WIRE)–Novaliq GmbH, società farmaceutica con una piattaforma di distribuzione di farmaci totalmente innovativa in grado di trasformare medicinali scarsamente solubili in terapie oftalmiche efficaci, ha oggi annunciato la registrazione in Europa di NovaTears®+Omega-3 per il miglioramento del trattamento dei segni e dei sintomi dell’occhio secco evaporativo (DED). NovaTears®+Omega-3 rappresenta una rivoluzione tecnologica nel trattamento dell’occhio secco evaporat
Ocular Therapeutix™ to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that management will be hosting investor meetings at the Guggenheim Securities 5th Annual Boston Healthcare Conference on Wednesday, December 13, 2017 at The InterContinental Boston Hotel in Boston, Massachusetts. Investors attending the conference who